leadf
logo-loader
AIM:ERGO

Ergomed PLC

Receive alerts
Market:
AIM
Market Cap:
£387.3 m
Price
800.00 GBX
Change
1.27%
52 weeks high
810.00
52 weeks low
258.00

With over 20 years of experience, we offer custom made development solutions in every stage of development from proof of concept to late stage programmes.

Founded in 1997, Ergomed plc is dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Operating with a global footprint in over 55 countries, Ergomed enables our clients to access solutions even for their toughest clinical development and trial management challenges from early phase to complex late stage programmes. Ergomed has provided and managed clinical development, trial management and pharmacovigilance services for over 100 clients: these ranging from top 10 pharmaceutical and generics organizations to small and mid-sized drug development companies.

Overview

Orphan Drug Development

Orphan drug trials are not just smaller versions of large trials and have specific requirements. We focus on the rare disease patient, and how to make a positive impact on their lives.

Therapeutic Expertise

Study experience is at the heart of what makes a CRO successful.

Clinical Expertise: Phase I-IV

Complete solutions for all phases of drug development.

Site Support Services

Our unique approach to Site Management ensures effective patient recruitment reducing time and cost of clinical trials.

CRO Resources

Industry specific information to provide guidance on the industry's complex changes, updates and challenges.

United Kingdom, Croatia, Germany, Russia, USA, Serbia, Poland, Ukraine, Switzerland, Bosnia and Herzegovina, UAE, India, KSA, Taiwan, Italy, Czech Republic and The Netherlands.

Dr Miroslav Reljanović

Founder and Executive Chairman

Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. Miro founded Ergomed in 1997 and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies.

Miro successfully introduced the first European co-development business model and he has completed several partnerships with European and North American listed biopharmaceutical companies. Miro co-founded PrimeVigilance in 2008 and it soon became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry.

Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange in July 2014 and the subsequent completion of five acquisitions and a secondary offering.

Miro is a director of Asarina Pharma AB (listed on the Nasdaq First North exchange), and Modus Therapeutics Holding AB, both Swedish-incorporated companies in which Ergomed plc has an equity stake through co-development arrangements.

Miro brings to the Board his in-depth experience in clinical development and the operational execution of drug development, as well as a detailed knowledge of the Group and its
operations.

 

Dr Jan Petracek

Chief Operating Officer

Dr. Jan Petracek was appointed to the Board as Chief Operating Officer in December 2017 and has been Chief Executive Officer of PrimeVigilance since April 2017. He joined the Ergomed group in November 2016 following the acquisition of European PharmInvent Services s.r.o., where he was founder and CEO. Dr. Petracek is the former Head of Risk Management at the European Medicines Agency and the former Head of Pharmacovigilance, Strategy and Development at the State Institute for Drug Control in the Czech Republic. Dr. Petracek was the EU Qualified Person responsible for pharmacovigilance at Vertex Pharmaceuticals, Biogen and BluePrint Medicines.

Dr. Petracek studied Quality and Safety in Healthcare (MSc) at Imperial College London and trained as a physician at Charles University in Prague (MD).

Dr. Petracek sits on the Advisory Board of the International Society of Pharmacovigilance and is a regular speaker at international pharmacovigilance conferences and training seminars.

Dr. Petracek keeps his skillset up-to-date by attending pharmacovigilance conferences and courses, and attending leadership coaching and business mentoring sessions.

As the founder of several successful organisations, Dr. Petracek brings entrepreneurship, business acumen and a track record of innovation in pharmacovigilance to the Board. As a senior ex-regulator, he has a deep understanding of the pharmaceutical regulatory environment.

 

Richard Barfield

Chief Financial Officer

Richard joined Ergomed as Chief Financial Officer in June 2019. Since qualifying as a chartered accountant, Richard has more than 25 years’ experience at Chief Financial Officer level in the healthcare, technology and business services sectors in US multinational companies as well as in UK-listed and PE-backed businesses. His expertise includes turnarounds, fundraisings, acquisitions and disposals, and he has extensive international experience. Richard has also held roles as Chief Executive Officer, Chairman, and Audit Committee Chairman of UK-listed companies as well as serving as a Board Member of an NHS Foundation Trust.
Richard has proven experience within the contract research sector, having most recently been Chief Financial Officer at Chiltern International Ltd from July 2013 to March 2018, which was a leading global mid-tier private CRO. During his five years at Chiltern, Richard was instrumental in transforming the corporate finance and strategy of the business, enabling it to grow revenues from $160m to $550m and deliver significant returns to its investors.

 

Peter George

Non-executive and Senior Independent Director

Peter George joined Ergomed as a non-executive director in May 2014. He became Ergomed’s Senior Independent Director in February 2019, having served as Non-Executive Chairman from April 2017 to January 2019.

Peter has over 20 years’ experience in the pharmaceutical services industry, most recently as Chief Executive Officer of Clinigen Group plc, the AIM-listed global speciality pharmaceuticals and pharmaceutical services business. Peter stepped down as CEO of Clinigen in November 2016. Prior to Clinigen, Peter was CEO at Penn Pharma, having led a £67 million management buy-out of the company in 2007.

Before this, Peter was executive Vice President for Wolters Kluwer Health with responsibility for Europe and Asia Pacific regions. Peter has also held roles as the Chief Operating Officer of Unilabs Clinical Trials International Limited, Head of Clinical Pathology in the Oxford region of the NHS and as a director of PharmaPatents Global.

Peter is currently Chair of Benchmark Holdings plc and Entrepreneur in Residence at Oxford Sciences Innovation.

He is also President of Enigma Holdings Ltd and Chairman of Mitre Group Limited, XPG Ltd, Marco Polo Events Limited, and Rent Plus Ltd, companies he owns or has significant holdings in.

Peter’s technical, commercial and business expertise in pharmaceutical services and experience of the AIM market environment enable him to provide valued guidance to the Board.

Peter is a member of Ergomed’s Audit and Risk Committee, Remuneration Committee and Nomination Committee.

 

Michael Spiteri

Non-Executive Director

Michael has held a number of senior leadership positions in the consulting industry and financial services industry over a 25 year period. He specialises in helping organisations implement technology that transforms their business and operating models and is currently the Global COO for Digital, Data and Development in HSBC’s Retail Banking and Wealth Management business.

Michael was previously a partner at PwC and held senior leadership positions at Accenture and IBM. He was involved in the early stages of telematics and the development of automation technology and business models in insurance and telecoms. Michael has a degree in Mechanical Engineering and designed real time computer solutions in the oil and gas industry in the early part of his career.

Michael brings his extensive experience in technological innovation to help the Board develop Ergomed’s business across digital, automation and machine learning.

Michael is Chair of Ergomed’s Remuneration Committee, and is a member of its Audit and Risk and Nomination Committees.

 

Rolf Soderstrom

Non-Executive Director

Rolf Soderstrom has over 30 years’ experience in finance and a track record of  accelerating the profitable growth of companies and delivering shareholder returns. Rolf has extensive strategic, operational and international experience including M&A, fundraisings and disposals.

During his time as CFO of BTG plc from 2008 to 2018, Rolf helped drive the successful transformation of the company into a fully integrated global manufacturing and sales organisation focused on specialist healthcare. As a key member of the leadership team he helped BTG grow from a small UK based business with 60 employees, to a global business with more than 1,500 people across North America, Asia and Europe. During this period the share price outperformed the FTSE 250 and the market capitalisation increased from approximately £400 million to £3 billion driven by a combination of organic growth and acquisitions.

Before joining BTG Rolf was Divisional Finance Director at Cobham Plc from 2004 to 2007 where he was responsible for a portfolio of 17 companies in Europe and the United States with combined turnover of £400 million. Prior to this he was Director of Corporate Finance at Cable & Wireless Plc. He qualified as a chartered accountant at PricewaterhouseCoopers where he worked initially in audit and then in the corporate finance function.

Rolf is Chair of Ergomed’s Audit and Risk Committee.

 

Dr. James Esinhart

Non-Executive Director

Dr. James Esinhart is an experienced leader in the clinical research industry with over 30 years working in biopharmaceutical companies, academia, and global clinical research organizations.

Most recently, Dr. Esinhart joined Chiltern International in 2006 and became CEO in 2012. Under his leadership, Chiltern was firmly established as a leading global mid-market CRO through the expansion of the company’s international footprint, multiple acquisitions and strategic investment in processes, people and technology. From 2006 to 2017 Chiltern’s growth was more than 11x, with revenue growing to over $550m and the global workforce to over 4,500. His successful tenure culminated in the sale of Chiltern to Covance, a division of the US-listed healthcare company Laboratory Corporation of America Holdings (LabCorp) in late 2017 for $1.2bn.

Dr. Esinhart has previously held several leadership positions in clinical research, including Vice President of Medical Data Sciences at Charles River and Inveresk. Prior to this time, he was co-founder and Senior Vice President of Biometrics at PharmaResearch Corporation. He was Assistant Professor at East Carolina University School of Medicine and also served on the university’s internal review board (IRB) for all research involving human subjects. In addition, he worked in clinical biostatistics product development roles at GlaxoSmithKline and Wyeth.

Dr Esinhart holds a PhD in Biostatistics from Virginia Commonwealth University School of Medicine in Richmond, Virginia, and a BS in Statistics from Radford University.

 

Sanja Jurić

General Counsel and Company Secretary

Sanja Juric joined Ergomed in 2016 after more than 30 years’ career in international law and after having assisted Ergomed as its outside advisor for more than 15 years. As Ergomed’s counsel, Sanja has been on Ergomed core co-development team since the first deal and helped close several co-development transactions.

Sanja holds degrees from the University of Zagreb (LLB, 1985) and the University of Fordham, School of Law, New York City (LLM in International Trade and Business Law, 1992). She has been admitted to the Bar of the State of New York since May 1993 and is listed as an arbitrator with the Chamber of Commerce in Croatia.

Sanja’s experience encompasses both in-house positions, including that of the head of legal affairs of the largest Croatian private company, during the period of its intense expansion via acquisitions and law firm positions. Prior to joining Ergomed, Sanja provided consulting to international businesses and organizations (including IFC, DEG, Avon, Kleeman, Herbalife) and cooperated with multinational law firms (Baker & McKenzie) focusing on cross-border transactions, primarily M&A. Sanja wrote extensively for several international M&A handbooks and participated for many years as an author in the World Bank series of “Doing Business”.

Headquarters
United Kingdom

Ergomed plc
1 Occam Court, Guildford, Surrey GU2 7HJ
Phone: +44 (1483) 503 205Croatia
ERGOMED Istrazivanja Zagreb d.o.o.
Oreskoviceva 20A
10020 Zagreb
Phone: +385 1 4628 500

Germany
Ergomed GmbH
Herriotstraße 1, 60528
Frankfurt/Main, Germany
Phone: +49 69 3487288-0 

Russia
ERGOMED Clinical Research, LLC
Skakovaya Street 17, Building 2, Office 2714
Moscow 125040, The Russian Federation
Phone: +7 495 721 8533


USA
ERGOMED Clinical Research Inc.
c/o David B Plemons CPA, Inc.      8207 Callaghan Road, Suite 150
San Antonio, Texas 78230 USA
Phone: +1 210-591-1881

Serbia
ERGOMED d.o.o
Belgrade Office Park,
Djordja Stanojevica 12,
11070 Belgrade, Serbia
Tel: +381(0) 11 4048 651

Poland
ERGOMED sp. z o.o.
8 Kolowa Street; Krakow 30-134
Phone: +48 (12) 622 4470 

Ukraine
ERGOMED PLC I 20.
Esplanadna Street, Office 636I Kyiv, 01023, Ukraine
Phone: +381 (0) 2163 50840


Switzerland
ERGOMED Virtuoso Sarl
18, Avenue Louis-Casai, 1209 Geneva
Phone: +41 22 747 78 01Bosnia and Herzegovina
ERGOMED d.o.o.Sarajevo
Zmaja od Bosne 7-7a, 71000 Sarajevo
Phone: +387 33215 715

UAE
ERGOMED Clinical Research FZ-LLC
Dubai International Academic City Block N 03, Office N EO 05
P.O. Box 501708 I Dubai, UAE
Phone: +971 4 374 9785 

India
ERGOMED Clinical Research India Private Limited
Level 4,Dynasty Business Park,
Andheri-Kurla Road, Andheri (East),
Mumbai – 400059, Maharashtra,
India


KSA
Ergomed Clinical Research
PO Box 26628, Riyadh 13325
Tamkeen Tower, 24th Floor, Olaya Street, Al Yasmin, Riyadh
Saudi Arabia
Phone: +00966115117033 ext. 1181
Taiwan
Ergomed Clinical Research Co Ltd
Fl.2, No. 467, Section 6, Zhongxiao E. Rd.
Nangang District, Taipei City 115, Taiwan
Phone: +866 2 2783-6668

Italy
ERGOMED Clinical Research Ltd.
Cuneo
Via Silvio Pellico 4 cap 12100

Czech Republic
PrimeVigilance s.r.o.
Stetkova 18
140 00 Praha 4, Czech Republic
Phone: +420 774 497 834

USA
PrimeVigilance Inc.
Reservoir Place
1601 Trapelo Rd
Waltham, MA 02451 USA
Phone: +1 781-703-5540

The Netherlands
PSR The Orphan Experts
Antareslaan 41
2132 JE Hoofddorp
The Netherlands

Germany
Ergomed Center for Data Management and Statistics GmbH (CDS)
Im Mediapark 2, 50670
Cologne, Germany


Germany
PrimeVigilance
Herriotstraße 1, 60528
Frankfurt/Main, Germany
Phone: +49 69 3487288-0

United Kingdom
Haemostatix
BioCity Nottingham
Pennyfoot Street
Nothingham, NG1
1GF, United Kingdom

Nominated Adviser & Joint Broker

Numis Securities Limited
10 Paternoster Square
London
EC4M 7LT

Solicitors to the Company

Covington & Burling LLP
265 Strand
London
WC2R 1BH

Registrars

Share Registrars Limited
The Courtyard, 17 West Street
Farnham, Surrey
GU9 7DR

Auditor

KPMG
1 Stokes Place
St. Stephen’s Green
Dublin 2
Ireland

Financial PR (UK)

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

Financial PR (Continental Europe)

MC Services AG
Kaiser Friedrich Ring 5
40545 Dusseldorf
Germany